evipedia.ai
← Back

Thymosin Beta-4 for Health & Longevity

Evidence Review created on 09/06/2026 using AI4L / Opus 5

Also known as: TB-500, Tβ4, Thymosin β4, Timbetasin, RGN-259

Motivation

Thymosin beta-4 is a small protein that almost every cell in the human body makes, and that platelets release in quantity at the site of an injury. Its main known job is to manage the internal scaffolding that lets cells change shape and move, which places it at the centre of how damaged tissue rebuilds itself. Laboratories now make synthetic copies, and a shortened version sold as TB-500 circulates widely outside medical channels.

The peptide was first isolated from calf thymus tissue decades ago. Drug developers have since tested it as eye drops for a damaged cornea and as an injection given soon after a heart attack. Neither use has been approved anywhere. In parallel it became one of the most heavily traded compounds in the private peptide market, where people inject it for tendon and muscle injuries.

This review examines what the human trial record, the animal work, and the regulatory record actually show: where measured benefits exist, how large they are, what the safety record contains, and what has never been tested.

Benefits - Risks - Protocol - Conclusion

High-level orientation material on thymosin beta-4 from expert platforms and from narrative reviews written by the researchers who developed it.

Content from three priority platforms could not be included: foundmyfitness.com has one relevant item — Q&A #64, “Peptide Therapies—BPC-157, TB-500, & GHK-Cu” — but it is a members-only episode whose content sits behind a paywall and so cannot be verified or linked here, while searches of lifespan.io and chriskresser.com returned no article or episode on this peptide at all.

Grokipedia

  • Thymosin beta-4

    A dedicated, heavily referenced entry covering the peptide’s structure, its encoding gene, its actin biology and the trial record — a fast orientation before reading the primary sources.

Examine

No Examine.com article exists for thymosin beta-4. Examine.com covers dietary supplement and nutrition ingredients; thymosin beta-4 is an unapproved injectable peptide that cannot be sold lawfully as a supplement ingredient, so it falls outside that scope.

ConsumerLab

Systematic Reviews

This section lists the systematic reviews and meta-analyses indexed on PubMed that evaluate thymosin beta-4 in controlled human trials.

Only the efficacy side of the trade-off is represented. No systematic review or meta-analysis covers the principal risks — long-term adverse events, immune reactions to the peptide, or cancer signalling — so the risk side of this compound is unrepresented in the synthesised literature.

Mechanism of Action

Thymosin beta-4 is a 43-amino-acid peptide encoded by TMSB4X (the X-chromosome gene carrying its blueprint). Its defining action is binding free actin monomers — the subunits cells assemble into filaments to crawl, divide and close a wound — keeping a reserve cells draw on when moving. Outside the cell it activates integrin-linked kinase (ILK, an enzyme relaying signals from cell-surface adhesion receptors) and Akt (an enzyme that keeps stressed cells alive), which in mice cut cell death and improved heart function after cardiac injury. It also drives angiogenesis (growth of new blood vessels), pulls keratinocytes (surface skin cells) into wounds, and dampens inflammatory signalling.

A partly separate route runs through its N-terminal fragment: prolyl oligopeptidase (an enzyme cutting peptides next to proline) and the kidney enzyme meprin-α release Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline), a four-residue peptide that limits scarring and inflammation, which angiotensin-converting enzyme (ACE, the target of common blood-pressure medications) then destroys.

The two accounts compete: no dedicated cell-surface receptor has been identified, and some groups credit Ac-SDKP with most of the scar-limiting benefit while others credit actin handling and ILK signalling.

Pharmacologically it is a peptide, not a small molecule. Given intravenously from 42 to 1260 mg, plasma half-life ran in hours and lengthened with dose. Its selectivity is for monomeric actin, not a receptor. It distributes into plasma, platelets and wound fluid rather than one organ, and peptidases — not the cytochrome P450 drug-metabolising enzymes (CYP3A4 and relatives) — clear it, so liver-enzyme interactions do not apply.

Historical Context & Evolution

Thymosin beta-4 came out of the search for thymic hormones. Working at George Washington University from the late 1960s onward, Allan Goldstein’s group fractionated calf thymus extract looking for factors that restored immune function, and the peptide was chemically characterised in 1982 as one product of that programme. Its expected role as an immune hormone did not hold up. The peptide turned out to be present in nearly all cells, and by the early 1990s its function had been reassigned to holding a reserve of actin — an internal housekeeping job rather than a hormonal one.

That reassignment is what opened the health-optimisation interest. If a peptide released by platelets at an injury site governs cell migration, it might accelerate repair. Rodent work through the late 1990s showed faster skin and corneal resurfacing, and a 2004 report in Nature that systemic thymosin beta-4 activated integrin-linked kinase and improved cardiac outcomes after a heart attack in mice moved the compound from dermatology into cardiology.

Goldstein founded RegeneRx Biopharmaceuticals to commercialise it, and essentially the entire subsequent trial programme — ocular, dermal and cardiac — has been run by RegeneRx, its joint venture ReGenTree, HLB Therapeutics or Beijing Northland Biotech, each of which holds a direct financial stake in a positive result. The bodybuilding market adopted the 17–23 fragment as TB-500 during the 2000s, well ahead of any human efficacy data, and the World Anti-Doping Agency added thymosin-β4 and its derivatives to its prohibited list in 2018.

Expected Benefits

For an audience willing to source and self-administer an unapproved peptide, the practical question is not whether thymosin beta-4 does something in a rodent, but which effects have been measured in people and how reliably they reproduce.

High 🟩 🟩 🟩

No benefit reaches High: the one outcome class measured repeatedly in humans — validated corneal staining and symptom scores in dry eye — disagrees across the three largest placebo-controlled trials, and every other human outcome comes from a single trial or from small dose-ranging trials that were not confirmatory.

Medium 🟩 🟩

Improvement of Scalp Seborrheic Dermatitis

A randomized trial in 71 people with scalp seborrheic dermatitis (an inflammatory scalp condition causing flaking and redness) compared a recombinant thymosin beta-4 gel against 2% ketoconazole, an established antifungal treatment, and against placebo over four weeks. Flaking and redness fell further on the peptide, and the scalp’s microbial mix shifted towards a healthy composition. Evidence is a single trial with no independent replication.

Magnitude: Scalp flaking improved more than on placebo at every follow-up point (p < 0.001, where p is the probability a difference this large would arise by chance) and redness area at the two-week post-treatment visit (p = 0.0103), with the flaking advantage still present 20 weeks on; the trial reports significance levels rather than a between-group effect size, so the literature gives no outcome figure.

Low 🟩

Relief of Dry Eye Signs and Symptoms ⚠️ Conflicted

Thymosin beta-4 eye drops cut ocular discomfort and corneal damage versus vehicle in a 9-patient Phase 2 trial and a 72-patient Phase 2 trial; two of three Phase 3 trials missed their primary endpoints, a strong vehicle response being the reason offered. Net: a real but unreliably reproduced symptomatic effect.

Magnitude: Ocular discomfort fell 35.1% and total corneal fluorescein staining 59.1% versus vehicle at day 56 (p = 0.0141 and p = 0.0108) in the 9-patient trial; the 72-patient trial showed a 27% discomfort reduction (p = 0.0244) while both of its primary endpoints failed.

Healing of Persistent Corneal Defects in Neurotrophic Keratopathy ⚠️ Conflicted

In neurotrophic keratopathy (nerve damage leaves the cornea unable to repair itself), the drops healed more defects than vehicle, but the trial was tiny and the primary comparison missed significance; a European Phase 3 later failed outright on an unexpectedly strong placebo response. Net: a promising, unconfirmed healing signal.

Magnitude: Complete healing at four weeks in 6 of 10 treated eyes versus 1 of 8 on vehicle (p = 0.0656); the Cochrane synthesis reports a risk ratio (how many times more likely the outcome is on treatment) of 9.00, 95% confidence interval (the range of values consistent with the data) 0.57 to 141.88.

Closure of Chronic Skin Ulcers

Topical thymosin beta-4 was tested on venous stasis ulcers (open sores caused by poor leg vein drainage) and on pressure sores in two sponsor-run Phase 2 trials. Both were dose-ranging rather than confirmatory, and the advantage appeared at one concentration only.

Magnitude: Roughly 25% of the patients receiving the 0.03% dose healed completely within three months — mainly those with small-to-moderate ulcers — out of 73 randomised across all arms; the investigators report healing about a month faster among patients who healed at all.

Cardiac Functional Recovery After a Heart Attack

In a 96-patient placebo-controlled trial after ST-segment elevation myocardial infarction (the most severe form of heart attack), infarct size fell only in those dosed within eight hours; the overall comparison was null. A ten-patient pilot using the peptide to pre-treat transplanted cells improved walking capacity.

Magnitude: Infarcted area at 90 days was significantly smaller in the 43 patients dosed within eight hours, with no significant difference across all 96 randomised; in the pilot, six-minute walk distance rose 75.7 m with pre-treated cells versus 38.2 m with untreated cells, a 37.5 m difference (95% confidence interval 28.7 to 56.3; p < 0.01).

Speculative 🟨

Tendon, Ligament and Muscle Repair

The dominant reason people buy TB-500, yet supported only by animal work: a 2026 rat Achilles study reported tissue-level and mechanical gains. No controlled human trial has measured tendon or muscle healing.

Hair Regrowth

Thymosin beta-4 accelerated hair growth in rats by activating follicle stem cells. The basis is animal only; no human trial has tested the peptide for hair loss of any kind.

Reduced Organ Scarring

Through the Ac-SDKP fragment, the peptide reduces scarring in rodent heart, kidney and lung injury models, per a narrative review of that axis. Entirely preclinical: no human study has measured scar tissue on treatment.

Neuroprotection and Cognitive Preservation

Human brain-organoid work identifies thymosin beta-4 as an Alzheimer’s disease target, and mouse work reports reduced plaque load. No human outcome data exist.

Benefit-Modifying Factors

  • ACE insertion/deletion genotype: Angiotensin-converting enzyme degrades the Ac-SDKP fragment. Carriers of the high-activity deletion/deletion genotype clear it faster, which plausibly blunts any scar-limiting component of the response, though no trial has stratified on this.

  • Prolyl oligopeptidase activity: This enzyme performs the cleavage that liberates Ac-SDKP from thymosin beta-4. Reduced activity — genetic or drug-induced — would limit that arm of the effect while leaving actin-dependent effects intact.

  • Baseline inflammatory and blood-sugar status: The clearest ulcer-healing signal appeared in small-to-moderate wounds. High inflammatory load, poor blood-sugar control and impaired tissue blood supply all slow the repair processes the peptide is meant to accelerate.

  • Sex: No sex-based difference in efficacy has been demonstrated. The Phase 1 programmes enrolled equal numbers of men and women and reported no divergence, and no trial has been powered to detect one.

  • Pre-existing conditions: Corneal nerve loss, venous insufficiency and diabetes define the populations in which any benefit has been measured. Someone without impaired repair has no measured baseline from which the peptide could improve anything.

  • Age: Repair capacity falls with age and the thymus shrinks, which is the premise for longevity interest. It also means older users start further from normal healing — the direction of the resulting effect on response is untested.

Potential Risks & Side Effects

Because no regulator has approved this peptide, there is no prescribing information and no post-marketing surveillance system. Everything below comes from trial adverse-event tables, human tissue studies, or mechanistic reasoning.

High 🟥 🟥 🟥

Transient Mild-to-Moderate Adverse Events

Across two placebo-controlled Phase 1 programmes — 40 healthy adults given 42 to 1260 mg intravenously daily for 14 days and 84 adults given 0.05 to 25 µg/kg — adverse events were mild or moderate, self-limiting and no more frequent than on placebo, with no dose-limiting toxicity and no serious events. Ocular trials reported the same pattern. This covers weeks of supervised pharmaceutical-grade dosing, not months of self-injection.

Magnitude: Adverse events occurred in 56.8% of single-dose recipients versus 70% on placebo, and in 66.7% versus 83.3% in the multiple-dose cohort; no serious adverse events or dose-limiting toxicities were recorded in either programme.

Medium 🟥 🟥

Antibody Formation Against the Peptide

Repeated dosing with a manufactured copy of a human peptide can prompt the immune system to raise antibodies against it, which may blunt the effect or, rarely, cross-react with the body’s own version. The only trial that measured this found isolated positives that all reverted to negative. It has been assessed in one Phase 1 programme over ten days of dosing and nowhere else, so nothing is known about repeated cycles.

Magnitude: One of 108 samples tested positive after single dosing and two of 56 after ten days of dosing; every positive sample reverted to negative on follow-up.

Low 🟥

Signalling That Favours Tumour Progression

Thymosin beta-4 promotes new vessel growth and cell migration — the processes tumours exploit. In human tissue, higher expression tracks with lymph-node spread in breast cancer through HIF-1α (a low-oxygen sensing switch), and it drives invasion in colorectal cancer cells. This is observational, not interventional.

Magnitude: Direction only: expression rises alongside nodal spread in surgical breast-cancer specimens, and the association holds where tissue is oxygen-starved. The literature reports no outcome figure for administered thymosin beta-4, because no trial has followed cancer incidence on treatment.

Speculative 🟨

Injection-Site Reactions

Subcutaneous self-injection produces bruising, tenderness, blood pooling and, over repeated use at one site, fat loss beneath the skin. No thymosin beta-4 trial used this route, so the basis is extrapolation from injected peptides generally.

Contaminated or Misdosed Unregulated Product

Material sold as TB-500 is made for research use with no official drug-quality standards, so endotoxin (a fever-inducing bacterial residue), peptide impurities and wrong fill weights are plausible. No analysis quantifies this for thymosin beta-4.

Unwanted Vessel Growth in Eye or Vascular Disease

New vessel growth is harmful in proliferative retinopathy and wet macular degeneration (abnormal retinal vessel growth) and in unstable atherosclerotic plaque. The concern is mechanistic; no human study has reported vessel-related harm on thymosin beta-4.

Unknown Effects of Long-Term Dosing

Supervised human exposure has never exceeded a few weeks. Chronic self-administration over months or years — the way the peptide is actually used privately — has no safety data of any kind behind it.

Risk-Modifying Factors

  • Hereditary cancer syndromes: Carriers of BRCA1/BRCA2 (genes whose products repair broken DNA) or Lynch syndrome variants (mismatch-repair genes) start from elevated malignancy risk, which magnifies the theoretical concern about a pro-angiogenic, pro-migratory peptide.

  • ACE genotype: The deletion/deletion genotype produces higher angiotensin-converting enzyme activity and faster Ac-SDKP breakdown. Its effect is to shorten exposure to the fragment rather than to raise any identified hazard.

  • Baseline biomarkers: An abnormal baseline cancer screen, an elevated inflammatory marker of unexplained origin, or an untreated retinal finding each converts a theoretical vessel-growth concern into a concrete reason not to proceed.

  • Sex: No sex-based difference in adverse events has been demonstrated; Phase 1 cohorts were sex-balanced and showed none. Pregnancy and lactation were exclusion criteria in every trial, so no data exist there.

  • Pre-existing conditions: Active malignancy, proliferative diabetic retinopathy and unstable coronary disease are the conditions in which the peptide’s vessel-growing action is most plausibly harmful rather than helpful.

  • Age: Cancer prevalence and undetected malignancy both rise with age, so the same theoretical tumour-signalling concern carries more absolute weight at 70 than at 40, alongside more medications taken at once.

Key Interactions & Contraindications

  • ACE inhibitors (lisinopril, ramipril, enalapril) — additive, monitor: These block the enzyme that degrades Ac-SDKP, raising circulating levels of the fragment several-fold. The combined scar-limiting effect is unstudied; blood pressure and kidney function warrant routine monitoring.

  • Anticoagulants and antiplatelet agents (warfarin, apixaban, clopidogrel, aspirin) — caution: No pharmacological interaction is described, but subcutaneous injection into anticoagulated tissue raises bruising and blood-pooling risk. Fine-gauge needles and firm post-injection pressure are the usual mitigation.

  • Anti-angiogenic cancer and retinal drugs (bevacizumab, ranibizumab, aflibercept) — caution, opposing action: Thymosin beta-4 promotes the vessel growth these agents are prescribed to suppress. Concurrent use risks undermining treatment; separation in time does not resolve the conflict.

  • Systemic corticosteroids (prednisone, dexamethasone) — monitor: Steroids suppress the inflammatory and proliferative phases of wound repair that thymosin beta-4 is meant to accelerate, plausibly cancelling any healing benefit without adding a safety hazard.

  • Non-steroidal anti-inflammatory drugs, over the counter (ibuprofen, naproxen, aspirin) — caution: Chronic use blunts the early inflammatory phase of tissue repair. Where a healing endpoint matters, limiting these to the minimum effective period is the usual mitigation.

  • Over-the-counter antihistamines and proton-pump inhibitors (acid-suppressing stomach medications; loratadine, omeprazole) — no interaction identified: Peptidase clearance and the absence of cytochrome P450 involvement make metabolic interaction with common over-the-counter medication implausible.

  • BPC-157 and other regenerative peptides — additive, unstudied: Frequently stacked with thymosin beta-4 for the same tissue-repair goal. Both promote angiogenesis, so the theoretical tumour-signalling concern is additive rather than independent.

  • Supplements with additive vessel-growth or antiplatelet effects (fish oil, curcumin, high-dose vitamin E, ginkgo) — caution: These raise bruising risk at injection sites; curcumin and fish oil also modulate angiogenesis, compounding the same uncertainty.

  • Supplements supporting the same endpoint (collagen peptides, vitamin C, zinc, arginine) — additive, benign: These support the collagen deposition and cell migration thymosin beta-4 is proposed to drive. No hazard is described; no combination has been formally tested.

  • Other interventions (platelet-rich plasma, hyperbaric oxygen, peptide receptor therapies) — additive, unstudied: All converge on angiogenesis and cell migration. Sequencing them makes any individual contribution impossible to attribute.

Populations who should avoid Thymosin Beta-4:

  • Anyone with active malignancy, or a malignancy treated within the past 5 years, excluding adequately treated non-melanoma skin cancer
  • Anyone with proliferative diabetic retinopathy or neovascular (wet) age-related macular degeneration
  • Anyone within 6 months of an acute coronary syndrome, stroke or transient ischaemic attack (a brief stroke-like episode), or with New York Heart Association Class III–IV heart failure
  • Pregnant or breastfeeding individuals, and anyone of childbearing potential not using effective contraception
  • Anyone competing under a World Anti-Doping Agency code, in which thymosin-β4 and its derivatives are prohibited at all times
  • Anyone with known hypersensitivity to peptide or biologic products
  • Anyone with severe kidney impairment (estimated glomerular filtration rate below 30 mL/min/1.73 m²) or liver impairment at Child-Pugh Class B or C, where no exposure data exist

Risk Mitigation Strategies

  • Cancer screening before the first course: Age-appropriate screening plus any indicated imaging addresses the tumour-signalling concern, the only risk here with human tissue evidence behind it. It then repeats on the normal population schedule.

  • Baseline dilated retinal examination: A single examination rules out proliferative retinopathy and wet macular degeneration, the two conditions in which the peptide’s vessel-growing action would plausibly do harm rather than good.

  • Batch certificate of analysis: Mass-spectrometry identity, purity above 98%, and a bacterial endotoxin result below 5 endotoxin units per kg per hour mitigate the contamination and misdosing risk inherent in research-grade material.

  • Bacteriostatic reconstitution and cold storage: Bacteriostatic rather than sterile water, storage at 2–8 °C, and discarding vials after 28 days limit microbial growth and injection-site infection after reconstitution.

  • Injection-site rotation: Alternating abdominal and thigh sites at least 2 cm apart, with a 29–31 gauge needle, reduces injection-site bruising, fat loss under the skin and blood pooling, particularly under antiplatelet or anticoagulant therapy.

  • Initial course capped at 4–6 weeks: Limiting a first course to the exposure duration supervised trials actually covered keeps use inside the window with adverse-event data, mitigating the unknown long-term dosing risk.

  • Stopping rules for new signs: Immediate cessation and clinical assessment on a new mass, unexplained bleeding or visual change limits exposure should the theoretical vessel-growth or tumour-signalling concerns materialise.

Therapeutic Protocol

  • The two competing approaches: Trial-based administration (ophthalmic solution or supervised intravenous dosing) and unregulated subcutaneous self-injection are separate practices with separate evidence bases. Neither is the established default; only the first has trial data.

  • Ophthalmic protocol (ReGenTree and HLB Therapeutics): 0.1% RGN-259 preservative-free solution, four times daily for 14–28 days in the ARISE dry eye programme and five times daily for 28 days in the SEER keratopathy programme.

  • Intravenous cardiac protocol (Beijing Northland Biotech): 10 or 20 µg/kg as a slow intravenous bolus within four hours of reopening the blocked artery, then once daily for seven days. Earlier work by RegeneRx used far larger fixed doses.

  • Topical dermal protocol (RegeneRx): 0.01% to 0.1% gel applied once daily to a cleaned, compression-dressed chronic ulcer. The 0.03% concentration produced the clearest signal in the venous ulcer trial.

  • Subcutaneous protocol used in peptide and longevity clinics: Commonly 2–2.5 mg twice weekly for 4–6 weeks, then 2–2.5 mg every one to two weeks. No trial has evaluated this route, dose or schedule.

  • Best time of day: No circadian data exist. Evening dosing is conventional in clinic protocols on the reasoning that repair processes concentrate during sleep; this is a rationale, not a finding.

  • Half-life and dosing frequency: Plasma half-life runs in hours and lengthens with dose, which is why trial protocols use daily dosing rather than intermittent dosing and why twice-weekly clinic schedules rest on tissue retention assumptions.

  • Single versus split dosing: Every trial used a single daily dose; none tested splitting. Given a half-life measured in hours, splitting would raise time above threshold, but this has never been examined.

  • Genetic influences on dose: ACE insertion/deletion and prolyl oligopeptidase variants alter Ac-SDKP exposure and are the obvious candidates for dose adjustment, yet no trial has genotyped participants or adjusted dose accordingly.

  • Sex-based dosing: No trial has used sex-adjusted dosing. The intravenous programmes dosed by body weight in µg/kg, which absorbs most of the average body-size difference between men and women.

  • Age-related adjustment: No age-stratified dosing exists. Trials enrolled up to age 75; adults beyond that range have no exposure data, and reduced kidney peptidase capacity would plausibly extend exposure.

  • Baseline biomarkers influencing response: Inflammatory load, blood-sugar control and tissue blood supply determine how much repair capacity is impaired to begin with, and therefore how much room a repair-promoting peptide has to work.

  • Pre-existing conditions influencing response: Diabetes, venous insufficiency and corneal nerve loss define the settings where a measurable effect has been observed. Outside impaired-healing states, no benefit has been demonstrated at any dose.

Discontinuation & Cycling

  • Intended duration: Every protocol with human data is short-term. The ophthalmic and dermal courses ran 28 days, the intravenous cardiac course seven days. Nothing supports indefinite or lifelong use.

  • Withdrawal effects: None have been reported. Trials that stopped dosing abruptly at day 28 recorded no rebound, and the corneal-healing trial found defects stayed closed two weeks after cessation.

  • Tapering: No taper is used or needed. All trial protocols stopped dosing outright at the end of the course, and no dose-dependent physical dependence has been described.

  • Cycling for efficacy: Cycling is standard in clinic protocols — typically 4–6 weeks on followed by an equal or longer break — but no trial has compared continuous with cycled dosing, so the rationale is theoretical.

  • Rationale offered for cycling: Practitioners cite receptor-independent tolerance and the wish to limit cumulative exposure to an untested compound. The second reason is defensible on precautionary grounds; the first has no supporting data.

Sourcing and Quality

  • No approved pharmaceutical source exists: Thymosin beta-4 is not approved anywhere. Pharmaceutical-grade material exists only as investigational product held by ReGenTree, HLB Therapeutics and Beijing Northland Biotech, and is not obtainable outside a trial.

  • Compounding status is contested: The U.S. Food and Drug Administration proposed against adding TB-500 to the Section 503A bulk drug substances list, and its advisory committee reviewed the substance in July 2026. Compounding-pharmacy availability therefore varies and may change.

  • What material is actually sold: Almost all supply is research-use freeze-dried powder from peptide synthesis houses, sold with no official drug-quality standard, no batch release testing requirement and no regulatory recourse if content is wrong.

  • Contents of a meaningful certificate of analysis: A batch-specific document showing mass-spectrometry identity confirmation, high-performance liquid chromatography purity above 98%, a quantified bacterial endotoxin result, and residual solvent and acetate content.

  • Sequence sold under the same name: Full-length 43-amino-acid thymosin beta-4 and the seven-residue 17–23 fragment are both marketed as TB-500 and are not interchangeable. Only the full-length peptide matches the trial evidence.

  • Third-party testing is the only realistic check: Independent laboratories will run identity and purity on a submitted vial. Vendor-supplied certificates are frequently generic rather than batch-specific and cannot substitute for this.

  • Storage and reconstitution: Freeze-dried powder is stable refrigerated; once reconstituted with bacteriostatic water, the solution keeps at 2–8 °C, protected from light, and is discarded after roughly 28 days.

Practical Considerations

  • Time to effect: Ocular symptom improvement appeared within one to two weeks in trials; corneal defect closure took four weeks; chronic ulcer closure took up to three months. Musculoskeletal timelines are anecdotal.

  • Common pitfall — buying the wrong molecule: The seven-residue fragment and the full 43-amino-acid peptide are sold under the same name at very different prices. The trial evidence applies only to the full peptide.

  • Common pitfall — extrapolating route and dose: Every human efficacy signal comes from eye drops, topical gel or intravenous dosing. Subcutaneous self-injection for tendon repair has no trial precedent at any dose.

  • Common pitfall — stacking: Combining thymosin beta-4 with BPC-157 and other repair peptides makes individual attribution impossible and compounds the shared, unquantified angiogenesis concern.

  • Regulatory status: Not approved as a drug in any jurisdiction and not lawful as a dietary supplement ingredient in the United States or Canada. There is no legitimate off-label pathway, since there is no approved label.

  • Anti-doping status: The Prohibited List bans thymosin-β4 and its derivatives at all times under the peptide hormones and growth factors class. Any tested competitor faces a multi-year sanction.

  • Cost and accessibility: Research-grade material is inexpensive relative to approved biologics, typically tens of dollars per 5 mg vial, but the real cost is the absence of quality assurance rather than the price.

Interaction with Foundational Habits

  • Sleep: No direct interaction. Trials recorded no sleep-related adverse events. The indirect link runs the other way: growth hormone release and tissue repair concentrate in slow-wave sleep, so inadequate sleep constrains the same repair processes the peptide is meant to amplify. Evening dosing in clinic protocols rests on this reasoning rather than on data.

  • Nutrition: Indirect and permissive. Actin-driven cell migration and collagen deposition require adequate protein, vitamin C and zinc; a deficit in any of these caps the achievable repair regardless of peptide exposure. No food interaction, absorption issue or nutrient depletion has been described, and the injectable and topical routes bypass the digestive tract entirely.

  • Exercise: Potentiating in principle, untested in practice. Mechanical loading drives tendon and muscle remodelling, and the peptide is bought precisely to support that remodelling. No trial has combined the two. The practical risk runs the other way: perceived early relief may prompt a return to full loading before the tissue has recovered.

  • Stress management: Indirect and blunting. Sustained cortisol elevation suppresses the inflammatory and proliferative phases of wound repair in the same way corticosteroid medication does, which plausibly cancels the peptide’s proposed effect. No study has measured cortisol or the stress response on treatment, so the interaction remains inferred from steroid pharmacology.

Monitoring Protocol & Defining Success

Baseline testing serves one purpose here: establishing that nothing the peptide could plausibly worsen is already present. Before a first course, that means age-appropriate cancer screening, a dilated retinal examination, a complete blood count, a comprehensive metabolic panel covering liver enzymes and kidney function, and a high-sensitivity inflammatory marker. For anyone using it for a specific injury, an objective functional measure of that injury — range of motion, grip strength, a validated pain score — recorded before the first dose is what makes any later judgement possible.

Ongoing monitoring is light because the exposure is short. The metabolic panel and inflammatory marker are repeated at 6 weeks, at the end of the first course, then every 6–12 months if courses are repeated. Cancer screening returns to the normal age-appropriate schedule rather than an accelerated one.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
High-sensitivity C-reactive protein (hs-CRP) Below 0.5 mg/L Tracks the inflammatory load the peptide is proposed to reduce hs-CRP is a general marker of body-wide inflammation. Conventional laboratories call anything under 3.0 mg/L normal; fasting sample, and testing is deferred for 2 weeks after any infection
Complete blood count with differential Platelets 175–250 ×10⁹/L; white cells 3.5–6.0 ×10⁹/L Platelets are the body’s main store of this peptide; also detects injection-related infection Conventional laboratories accept 150–400 ×10⁹/L platelets and 4.0–11.0 ×10⁹/L white cells, both far wider than the functional targets; best drawn at the same time of day and paired with the metabolic panel
Alanine aminotransferase (ALT) Below 25 U/L in men, below 20 U/L in women Baseline organ safety before an unapproved injectable ALT is a liver enzyme released when liver cells are stressed. Conventional upper limits run to 40–55 U/L, well above the functional target; fasting preferred
Estimated glomerular filtration rate (eGFR) Above 90 mL/min/1.73 m² Kidney enzymes help clear this peptide, and severe impairment is an exclusion eGFR is a calculated measure of kidney filtering capacity. Paired with cystatin C, an alternative kidney marker, where muscle mass is high; conventional concern threshold is 60
Haemoglobin A1c (HbA1c) 4.8–5.4% Poor blood-sugar control independently impairs the wound healing being targeted HbA1c is average blood sugar over about three months. Conventional threshold for prediabetes is 5.7%; unaffected by fasting
Prostate-specific antigen in men, or age-appropriate cancer screening No established target for this use; the individual’s own baseline is the reference, and change from it is what is tracked Addresses the tumour-signalling concern, the only risk with human tissue evidence Any rising trend warrants assessment before a further course, not after
Antibodies against thymosin beta-4 No established target, and no validated clinical assay is commercially available; loss of a previously observed response across repeat courses is tracked instead, against the individual’s own first-course record Would detect the immune response seen in the Phase 1 programme Available only within trials; listed here so its absence outside them is understood

Qualitative markers worth tracking alongside the laboratory work:

  • Pain and function in the specific tissue being targeted, scored the same way each time
  • Morning stiffness duration
  • Ocular comfort, grittiness and dryness for anyone using the ophthalmic route
  • Wound appearance, discharge and margin advance, photographed weekly under consistent lighting
  • Injection-site appearance, bruising and hardening
  • Sleep quality and daytime energy, as a check on general tolerability

Emerging Research

  • Phase IIc cardiac trial of recombinant thymosin beta-4: NCT07586865 plans to randomise 189 patients after a major heart attack to 10 µg/kg, 20 µg/kg or placebo, with infarct size on cardiac magnetic resonance imaging at day 90 as the primary endpoint.

  • SEER-2 corneal Phase 3 trial: NCT05555589 is recruiting 70 patients with neurotrophic keratopathy across 36 sites to test whether 0.1% eye drops five times daily close persistent corneal defects by day 29 — the endpoint the European Phase 3 missed.

  • Newly published cardiac trial data: Zhang et al. 2025 report a 96-patient randomised trial in which infarct size fell only among patients dosed within eight hours of the blocked artery being reopened; NCT05984134 has posted no registry results.

  • Evidence that could strengthen the case — the scarring axis: Wang, Jia & Zhang 2022 map the route by which the peptide’s Ac-SDKP fragment limits scarring across organs. Human confirmation would give the longevity claim its first outcome-level support.

  • Evidence that could strengthen the case — vascular repair: Su et al. 2022 restored function to vessel-lining cells derived from patients with diabetes. Whether this translates to vascular outcomes in people is the open question.

  • Evidence that could weaken the case — tumour signalling: Piao et al. 2014 show the peptide driving colorectal cancer cell invasion through the same integrin-linked kinase pathway that underlies its repair effects, meaning benefit and hazard may be inseparable.

  • Evidence that could weaken the case — sponsor concentration: Almost every trial has one of four commercial sponsors. Independent replication is the single research development that would most change confidence, and none is currently registered.

Conclusion

Thymosin beta-4 is a small protein the body makes everywhere and releases at injury sites, where it governs the internal scaffolding cells use to move and rebuild tissue. That biology is well established. What follows from it in people is much less settled. Eye drops containing the peptide have relieved dry eye discomfort and surface damage in several trials, but the two largest trials did not confirm their main results. A course of the drops closed more damaged corneas than placebo in one small trial, while a later European trial found nothing. Skin ulcer trials produced a healing advantage at one concentration only. A gel form eased scalp flaking better than a standard antifungal in one trial. Everything else people buy it for — tendon repair, muscle recovery, hair, organ scarring, brain protection — rests on animals and cell cultures alone.

The safety record is reassuring as far as it goes: weeks of supervised dosing produced no more trouble than placebo. It says nothing about months or years of self-injection, and human tissue studies link higher levels of this peptide to cancer spread, which nobody has followed on treatment. Almost every trial was funded by a company that stands to gain from a positive result, and no independent group has repeated the work. For someone weighing a compound bought outside regulated channels, that combination — real biology, thin and inconsistent human results, and evidence generated almost entirely by interested parties — is the honest summary.

Top - Benefits - Risks - Protocol